Company: PRTA
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001559053-25-000023
Chunk: 4

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 4
---
 presented in the Company’s consolidated Balance Sheet.

The following table sets forth significant research and development (“ R& D”) expenses by program as regularly provided to the CODM (in thousands):

                                      Three Months Ended                                        
                                      March 31,                                                 
                                      2025                                2024                  
 ────────────────────────────────────────────────────────────────────────────────────────────────
  Birtamimab (NEOD001)                $                       25,914      $             21,184  
  PRX012                                                      18,075                    37,813  
  PRX019                                                       2,102      —                     
  Other R& D                                                   4,720                     5,117  
  Total research and development      $ 50,811                            $ 64,114              

Recent Accounting Pronouncements

On November 4, 2024, the Financial Accounting Standards Board (“ FASB”) issued Accounting Standards Update (ASU) 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures, which requires public business entities to disclose, on an annual and interim basis, disaggregated information about certain income statement line items in a tabular format in the notes to the financial statements. This guidance will be effective for the Company’s annual period ending December 31, 2027, and interim periods beginning January 1, 2028. Early adoption is permitted. Entities may apply the guidance prospectively or retrospectively. The Company is currently evaluating the impact of this new standard on its financial statement disclosures.

On March 6, 2024, the SEC issued final rule, “ The Enhancement and Standardization of Climate-Related Disclosures for Investors”, which requires registrants to disclose material climate-related risks, including descriptions of board oversight and risk management activities, the material impacts of these risks on a registrants strategy, business model and outlook and any material climate-related targets or goals. The rule requires these climate-related information to be disclosed in registration statements and annual reports. Registrants will also need to quantify certain effects of severe weather events and other natural conditions in a note to their audited financial statements. In addition, accelerated and large accelerated filers will need to disclose Scope 1 and Scope 2 greenhouse gas (GHG) emissions, if material, which will be subject to third-party assurance. The Company would be required to comply with the rule in fiscal year beginning January 1, 2025 for all disclosures other than the compliance with quantitative and qualitative disclosure requirements of